The lack of cytotoxicity to malignant cells with wt Ras or wt p53 limits the clinical application of this construct as a gene therapy to cancers with concomitant RAS and P53 mutations (e.g., pancreatic), but this was purposely arranged to increase the threshold for activation and safety margin of the construct in normal or non-malignant cells. Here, TP53 is linked to cancer.